Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M106981200 on August 29, 2001

J. Biol. Chem., Vol. 276, Issue 46, 43145-43151, November 16, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/46/43145    most recent
M106981200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shakkottai, V. G.
Right arrow Articles by Chandy, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shakkottai, V. G.
Right arrow Articles by Chandy, K. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Design and Characterization of a Highly Selective Peptide Inhibitor of the Small Conductance Calcium-activated K+ Channel, SkCa2*

Vikram G. ShakkottaiDagger §, Imed Regaya§||, Heike WulffDagger , Ziad Fajloun||, Hiroaki TomitaDagger , Mohamed Fathallah||**, Michael D. CahalanDagger , J. Jay GargusDagger , Jean-Marc Sabatier||, and K. George ChandyDagger

From the Dagger  Department of Physiology and Biophysics, University of California, Irvine, California 92697, || CNRS Unité Mixte de Recherche 6560, Faculté de Médecine Nord 13014, Marseille, France, and ** CIC 9502, Assistance Publique des Hôpitaux de Marseille-INSERM, Hôpital Sainte Marguerite, Marseille 13009, France

Received for publication, July 24, 2001, and in revised form, August 29, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Apamin-sensitive small conductance calcium-activated potassium channels (SKCa1-3) mediate the slow afterhyperpolarization in neurons, but the molecular identity of the channel has not been defined because of the lack of specific inhibitors. Here we describe the structure-based design of a selective inhibitor of SKCa2. Leiurotoxin I (Lei) and PO5, peptide toxins that share the RXCQ motif, potently blocked human SKCa2 and SKCa3 but not SKCa1, whereas maurotoxin, Pi1, Tskappa , and PO1 were ineffective. Lei blocked these channels more potently than PO5 because of the presence of Ala1, Phe2, and Met7. By replacing Met7 in the RXCQ motif of Lei with the shorter, unnatural, positively charged diaminobutanoic acid (Dab), we generated Lei-Dab7, a selective SKCa2 inhibitor (Kd = 3.8 nM) that interacts with residues in the external vestibule of the channel. SKCa3 was rendered sensitive to Lei-Dab7 by replacing His521 with the corresponding SKCa2 residue (Asn367). Intracerebroventricular injection of Lei-Dab7 into mice resulted in no gross central nervous system toxicity at concentrations that specifically blocked SKCa2 homotetramers. Lei-Dab7 will be a useful tool to investigate the functional role of SKCa2 in mammalian tissues.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ca2+-activated K+ (KCa)1 channels modulate cytosolic Ca2+ concentrations in excitable and non-excitable tissues by regulating the membrane potential. Based on their unitary conductance, KCa channels are classified as BKCa, IKCa, and SKCa (1). Opening in response to an increase in cytosolic [Ca2+]i in the 200-500 nM range (2), SKCa channels modulate the firing pattern of neurons by generating slow membrane after hyperpolarizations (3-5). In the liver, they are believed to play a role in metabolic stress responses (6), and in human Jurkat T cells, they promote calcium entry in response to a mitogenic stimulus (7). SKCa channels have also been implicated in fasciculations in denervated skeletal muscle (8) and in myotonic dystrophy (9). SKCa channels, products of three phylogenetically related genes SKCa1-3, are found in a variety of tissues including the nervous system (10), liver (11), skeletal and smooth muscle (8, 12), adrenal medulla (13), and lymphoid tissues (14, 15). In the brain (16), the precise functional role of each channel in specific neuronal pathways has been difficult to elucidate because of the absence of selective blockers. The identity of the specific SKCa channel(s) responsible for apamin-induced destruction of cerebellar Purkinje neurons (17) and altered seizure threshold (18, 19) and for apamin and Lei neurotoxicity (20) is also unclear. The development of inhibitors that target each of these channels selectively would facilitate studies to determine their specific roles in mammalian tissues.

The SKCa2 channel is expressed in the brain (10, 16), retina (21), liver (22), melanocytes (expressed sequence tag AA418096), fetal heart (expressed sequence tag AA418000), and human Jurkat T cell line (7, 22, 23). Precise determination of function has only been possible in Jurkat T lymphocytes in which this channel plays a role in calcium signaling (7, 14, 24). The existing blockers of SKCa2 channels are not adequately specific to distinguish this channel from other SKCa subtypes. Apamin, a peptide from bee venom, exhibits only 10-fold selectivity for human SKCa2 over human SKCa1 or SKCa3 (3, 22, 25, 26), while the bisquinolinium cyclophane UCL-1684 blocks SKCa2 and SKCa1 with roughly equivalent potency (25) although it shows some selectivity over SKCa3 (7). The peptide toxin Lei (also known as scyllatoxin) from the scorpion Leiurus quinquestriatus hebraeus, currently the most specific inhibitor of SKCa2, exhibits ~200-fold selectivity for human SKCa2 (15) over SKCa1 (25), although its affinity for SKCa3 had not been determined.

This study describes the guided design and electrophysiological characterization of a novel Lei analog that selectively blocks SKCa2 homotetramers with low nanomolar affinity. Our strategy to design a specific inhibitor of the SKCa2 channel exploited an approach used previously to develop selective blockers of Kv1.3 and IKCa1 channels (27, 28). In this approach, a potent yet non-selective inhibitor of the target channel is the starting template. Specificity for the desired channel is engineered into the peptide on the basis of experimentally determined differences in its interaction with the target channel and other channels. Using Lei and a closely related peptide PO5 as templates, and by comparing the potencies of the native and mutant toxins for SKCa1, SKCa2, and SKCa3, we delineated the channel-binding surfaces of these toxins. Lei-Dab7 was designed to target a structural feature unique to the Lei-SKCa2 interaction surface.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Peptide Synthesis-- N-alpha -Fmoc-L-amino acid derivatives, Fmoc-amide resin, and chemical reagents used for peptide synthesis were purchased from PerkinElmer Life Sciences (Shelton, CO), Novabiochem (Laufelfingen, Switzerland), and Neosystem Laboratoire (Strasbourg, France). Solvents were analytical grade products from SDS (Peypin, France). The various peptides were synthesized by the stepwise solid-phase method (29) using a peptide synthesizer (Model 433A, Applied Biosystems Inc., Foster City, CA). The side-chain protecting groups used for trifunctional residues were: 2,2,5,7,8-pentamethylchromane-6-sulfonyl for Arg and homoarginine; tert-butyloxycarbonyl for Orn, Lys, and homolysine, and 1-(4,4-dimethyl-2,6-dioxocyclohex-1-yliden)-3-methylbutyl for Dab and diaminopropionic acid (Dapa). The reduced peptides were dissolved at 1 mM in 0.2 M Tris-HCl buffer, pH 8.3, and stirred under air to allow folding/oxidation (48 h, 25 °C). The folded/oxidized toxins and their structural analogs were purified to homogeneity by reversed-phase high-pressure liquid chromatography (HPLC) (PerkinElmer Life Sciences), C18 Aquapore ODS 20 µm, 250 × 10 mm). The homogeneity (>99%) and identity of the peptides were verified by: (i) analytical C18 reversed-phase HPLC, (ii) amino acid content determination after acidolysis, and (iii) mass analysis by matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Cell Culture-- Jurkat E6-1, COS-7, and PC12 cells were obtained from ATCC (Manassas, VA). Jurkat E6-1 cells were grown in RPMI medium supplemented with 10% fetal bovine serum, 2 mM glutamine, and 10 mM HEPES at densities of 1-9 × 105 in a 37 °C humidified incubator with 5% CO2. COS-7 and PC12 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 2 mM glutamine and split twice weekly. Unless otherwise specified, all reagents were obtained from Sigma.

Clones and Mutants-- The cloning of human SKCa3 containing 19 polyglutamines in the N terminus (GenBankTM AF031815, AJ251016) and IKCa1 (GenBankTM AF033021) has been reported previously (30-32). The full coding region of SKCa1 was amplified from human brain total RNA using reverse transcriptase polymerase chain reaction (PCR) with an engineered 5' HindIII site near the start codon and a 3' BamHI site near the termination codon and was cloned in-frame into the pEGFP-C3 vector (CLONTECH, Palo Alto, CA) to create GFP-SKCa1. PCR was used to generate mutant SKCa3 channels (28). PCR products were digested with KpnI and BamHI and cloned into KpnI and BamHI-cut GFP-SKCa3. All clones were verified by sequencing. DNA for transfection was prepared with the QIAGEN (Valencia, CA) Miniprep kit. Human SKCa2 in pcDNA3 was a generous gift from Dr. Bernard Attali (Tel Aviv University, Sackler School of Medicine, Israel).

Transfection of Constructs into Mammalian Cells-- COS-7 cells were plated in culture chambers (5 × 105 cells/chamber), and 12-24 h later, cells were transiently transfected using FuGeneTM 6 (Roche Molecular Biochemicals) with the respective DNA in serum-free OptiMEM medium (Life Technologies, Inc.) as per the manufacturer's recommended protocol. GFP-positive cells were used for electrophysiological studies at 48 h following transfection. Typical transfection efficiencies using this protocol were 40-70%. PC12 cells were plated overnight on glass coverslips prior to use. Cell lines stably expressing mKv1.1, mKv1.3, and hKv1.5, hSlo, and RBL cells expressing endogenous rKir 2.1 were used for the selectivity screen as described previously (28).

Electrophysiology-- Cells were studied in the whole cell configuration of the patch clamp technique. The holding potential in all experiments was -80 mV. For measurement of IKCa, SKCa, and BKCa currents, we used an internal pipette solution containing (in mM) 145 potassium aspartate, 2 MgCl2, 10 HEPES, 10 K2EGTA, and 8.5 CaCl2 (1 µM free Ca2+), pH 7.2, 290-310 mOsm. KV currents were recorded with a fluoride-based internal solution. To reduce currents from native chloride channels in COS-7, sodium aspartate Ringer was used as an external solution (in mM) 160 sodium aspartate, 4.5 KCl, 2 CaCl2, 1 MgCl2, and 5 HEPES, pH 7.4, 290-310 mOsm. For Jurkat T cells, potassium aspartate Ringer was used as an external solution with K+ instead of Na+ (164.5 mM K+). SKCa currents were elicited by 200-ms voltage ramps from -120 to 40 mV applied every 10 s, and the reduction of slope conductance at -80 mV by the toxin was taken as a measure of channel block. BKCa currents were elicited by 200-ms voltage ramps from -80 to 80 mV applied every 30 s, and channel block measured at 35 mV. The inward rectifier (rKir 2.1) in RBL cells was studied in sodium aspartate Ringer with a potassium aspartate-based pipette solution containing 50 nM free Ca2+.

Selective in Vivo Blockade of SKCa2 Channels by Lei-Dab7 in Mice-- Lei-Dab7 was administered to 25-g C57/BL6 mice via the intracerebroventricular route, and the LD50 was determined (33). Groups of four mice per dose were injected with 5 µl of the peptide solution containing 0.1% (w/v) bovine serum albumin and 0.9% (w/v) sodium chloride.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Lei and PO5 Are Potent Inhibitors of Human SKCa Channels-- Six peptide toxins from scorpion venom have been identified as SKCa channel blockers based on 125I-apamin displacement studies on rat brain synaptosomes (34). Fig. 1 shows the sequence alignment of these toxins (35), three of which (Lei, PO5, and Pi1) contain a motif (RXCQ) reported to be important for binding to SKCa channels. (20, 36). Apamin contains an RRCQ sequence (Fig. 1), which has a spatial arrangement similar to that of the RMCQ motif in Lei (Fig. 2).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence alignment of known SKCa blockers showing subfamilies 4, 5, 6, and 8 from scorpion venom (28) and apamin. The conserved RXCQ motif is boxed. The differing residues of Lei and PO5 are highlighted. MTX, maurotoxin.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Superimposition of the backbone structures of Lei (yellow) and apamin (blue). The RXCQ motif is boxed. Inset, RXCQ motif in both toxins on a larger scale.

Lei is reported to block the well characterized human SKCa2 channel in Jurkat T cells with picomolar potency (15, 22, 23). As the first step in our strategy to design a specific SKCa2 inhibitor, we compared the potency of Lei with that of PO5, a toxin that differs from Lei only at positions 1, 2, 7, and 24 (Fig. 1), in blocking Jurkat SKCa2. Symmetric internal and external K+ solutions were used to induce the inward component of the SKCa2 current. Following break-in with 1 µM Ca2+ in the pipette solution, SKCa2 currents were seen at negative potentials. At potentials more positive than -40 mV, K+ currents were mainly due to Kv1.3 with minimal contribution from SKCa2 (Fig. 3A, left). The SKCa2 component was blocked by Lei and PO5, whereas the Kv1.3 current was unaffected (Fig. 3A, left). Dose-response curves showed that Lei blocked Jurkat SKCa2 with Kd values consistent with published data on the cloned and native channel (15, 22, 23) and with ~100-fold greater potency than PO5 (Fig. 3B and Table I). Lei and PO5 were next evaluated on cloned SKCa1 and SKCa3 expressed in COS-7 cells. SKCa1 (Fig. 3A, middle) and SKCa3 (Fig. 3A, right) K+ currents elicited with 1 µM Ca2+ in the pipette solution reversed at -80 mV in the presence of external sodium Ringer. Lei and PO5 blocked SKCa3 but were ineffective on SKCa1 (Fig. 3A and Table I). Comparison of the dose-response curves of SKCa3 showed Lei to be 25-fold more effective than PO5 (Fig. 3B and Table I). For reasons that remain unclear, four other scorpion toxins (maurotoxin, Pi1, PO1, and Tskappa ) reported to be highly active in 125I-apamin displacement assays (20, 34, 36) had little or no blocking activity on SKCa2 or SKCa3 (Table I). Thus, the two most potent scorpion peptides, Lei and PO5, exhibited significantly different blocking potencies on SKCa2 and SKCa3 despite differing at only four positions.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of Lei and PO5 on SKCa1-3. A, typical current traces on the three SK<UP><SUB>Ca</SUB><SUP>+</SUP></UP> channels showing block with Lei and PO5. SKCa2 and Kv1.3 (left); SKCa1 (middle); SKCa3 (right). B, dose-response curves of Lei and PO5 on SKCa1-3. Lei on hSKCa1 (triangle , straight line, Kd = 325 nM); Lei on hSKCa2 (black-square, straight line, Kd = 0.2 nM); Lei on hSKCa3 (, straight line, Kd = 1.1 nM); PO5 on hSKCa2 (black-square, dashed line, Kd = 22.1 nM); and PO5 on hSKCa3 (, dashed line, Kd = 25.1 nM). Only one concentration of PO5 was tested on SKCa1 (shown). Typical SKCa1-3 currents were studied in the whole cell configuration of the patch clamp technique. Recordings were done with 1 µM free calcium as the internal pipette solution, and currents were elicited by voltage ramps from -120 to 40 mV. SKCa1 and SKCa3 were expressed transiently in COS-7 cells. An external solution containing sodium aspartate (5 mM potassium aspartate) was used for the recordings, and the degree of block was measured as the decrease in slope conductance at -80 mV. Jurkat T-cells were used to assess the effect on endogenous hSKCa2 with symmetric internal and external potassium aspartate (165 mM potassium aspartate).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Comparison of competition data on rat brain synaptosomes of indicated toxins (20, 34, 36) with Kd values by patch clamp on hSKCa2 and hSKCa3

Ala1, Phe2, and Met7 in Lei Are Responsible for the Enhanced Potency of Lei over PO5-- To define the residues responsible for the increased affinity of Lei for SKCa channels, we replaced each of the four differing residues in PO5 with the corresponding residue in Lei. PO5-V24D blocked SKCa2 and SKCa3 with a potency comparable with native PO5 (Fig. 4A). PO5-T1A, PO5-V2F, and PO5-R7M blocked SKCa2 with potencies approaching that of Lei. The improved potency of all three PO5 mutants to nearly that of Lei suggests that any of the indicated alterations in the side chains at these positions may allow PO5 to fit more tightly within the channel-binding pocket due to either shorter side-chain size or local change in backbone conformation (37, 38). Similar results were obtained with these PO5 mutants on SKCa3 (Fig. 4B). The reverse mutation in Lei (Lei-M7R) reduced potency on both SKCa2 and SKCa3 (data not shown). These results indicate that Ala1, Phe2, and Met7 underlie the increased affinity of Lei over PO5 for SKCa2 and SKCa3. These three residues form a localized binding pocket that may represent an important contact point with SKCa channels (Fig. 5, A and B).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 4.   Histograms showing the effect of replacement of Thr1, Val2, Arg7, and Val24 in PO5 with the corresponding residues in Lei in blocking SKCa2 (A) and SKCa3 (B). The Kd values of native toxin is shown for comparison.


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 5.   Space-filling models of Lei (left) and PO5 (right) showing residues at positions 1, 2, 7, and 24 (A) and the conserved RXCQ motif (B). X = methionine in Lei and arginine in PO5.

Lei-Dab7 Is a Highly Selective Inhibitor of SKCa2-- Positions 6 and 7 of Lei are part of the conserved RXCQ motif (Fig. 1). To define the role of the residues in this motif, a series of Lei mutants was made at positions 6 and 7 to probe the toxin-channel interaction. Charge-neutralization mutations at position 6 that retained size (Arg6 right-arrow leucine or citrulline) reduced toxin potency 70-180-fold for both channels (Fig. 6), indicating the need for a charged residue at this position. Substitution of the unbranched lysine at position 6, a mutation that retained charge but decreased size, also reduced toxin affinity for both channels (20-35-fold), whereas the introduction of the positively charged, bulky branched unnatural amino acid, homoarginine, caused a 1000-fold decrease in toxin potency (Fig. 6). Thus, substitutions at position 6 are not tolerated, and the arginine has the optimum size, charge, and branching required for interaction with SKCa channels. Furthermore, when residues at positions 6 and 7 were exchanged, the Lei-R6M+M7R double mutant was considerably less potent than the native toxin on SKCa2 and SKCa3 (Kd = 9.5 and 65 nM, respectively), establishing the importance of the relative locations of Arg6 and Met7 in the RXCQ motif.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of substitutions at position 6 of Lei in blocking SKCa2 (left) and SKCa3 (right). The respective Kd values is shown on the right. Numbers in parentheses indicate the number of times tested.

We next turned our attention to position 7 in the RXCQ motif and found our first promising lead. Introduction of positively charged lysine at position 7 (Lei-M7K) yielded a mutant that blocked SKCa2 35-fold more potently than SKCa3 (Fig. 7). In an attempt to further enhance this difference, we generated two additional Lei mutants in which Met7 was replaced by smaller positively charged unnatural amino acids diaminopropionate (Lei-Dapa7) and diaminobutanoate (Lei-Dab7). Lei-Dapa7 blocked Jurkat SKCa2 ~350-fold more potently than SKCa3, whereas Lei-Dab7 was ~650-fold more effective. Similar results were obtained with the cloned SKCa2 channel expressed in COS-7 cells (Table II). Lei-Dab7 was also ineffective against hSKCa1, hIKCa1, hSlo, KV, and Kir channels, establishing its specificity for SKCa2 (Table II).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of substitutions at position 7 of Lei in blocking SKCa2 (left) and SKCa3 (right). The respective Kd values is shown on the right. Numbers in parentheses indicate the number of times tested.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Selectivity of Lei-Dab7 on a panel of channels Kd indicated on the right

Asn367 in the SKCa2 Pore Region Is Important for Lei-Dab7 Selectivity-- Because Lei-Dab7 and apamin share the critical RXCQ channel-binding motif (Figs. 1 and 2), it is likely that Lei-Dab7, like apamin (39), binds to residues in the external S5-Pore-S6 region of the channel. Human SKCa2 and SKCa3 differ at only two positions in the pore region (Fig. 8A). To determine whether one or both these residues contribute to Lei-Dab7 selectivity (Fig. 8, B and C), we replaced these two residues in SKCa3 (Val485 and His521) with the corresponding residues of SKCa2 (Ala331 and Asn367), individually or together. Lei-Dab7 blocked SKCa3-H521N (Kd = 20 ± 4.7 nM) and SKCa3-V485A + H521N (Kd = 7.5 ± 1.2 nM) with nearly the same potency as SKCa2 (Fig. 8, D and E, and Table II), whereas SKCa3-V485A did not produce functional channels. In mutant cycle studies with the SKCa3-H521N and SKCa3-V485A+H521N mutants, residue 7 of Lei-Dab7 was found to couple tightly with His521 (Delta Delta G = 2.4), suggesting that these two residues lie in close proximity to each other. We conclude that Lei-Dab7 binds to the external vestibule of SKCa channels and that Asn367 (the residue corresponding to His521 of hSKCa3) in SKCa2 contributes to Lei-Dab7 selectivity.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of replacement of differing residues in the S5-Pore-S6 region in SKCa3 with the corresponding residues in SKCa2. A, sequence alignment of SKCa2 and SKCa3 S5-Pore-S6 region with the two differing residues underlined. B, 10 nM Lei-Dab7 on native SKCa2 (Kd = 3.8 nM ± 0.5 nM). C, 1000 nM Lei-Dab7 on hSKCa3 (Kd = 2500 ± 500 nM). D, 100 nM Lei-Dab7 on hSKCa3-H521N (Kd = 20 ± 4.7 nM). E, 10 nM Lei-Dab7 on hSKCa3-V485A+H521N (Kd = 7.5 nM ± 1.2 nM).

Selective in Vivo Blockade of Homotetrameric SKCa2 Channels by Lei-Dab7 Does Not Cause Gross Neurotoxicity-- To evaluate the central nervous system effects of specific in vivo blockade of SKCa2 homotetramers, Lei-Dab7 was administered via the intracerebroventricular route to mice. At a concentration (10 ng (or 300 nM assuming a brain liquid volume of 10 µl)) that would selectively block >99% of SKCa2 homotetramers, no gross central nervous system toxicity was observed. At a higher concentration (50 ng (or 1500 nM)), all six animals became hyperexcitable, developed convulsions followed by paralysis lasting 15 h, and then fully recovered. At much higher concentrations (80 ng (or 2400 nM)), 50% of the animals died within 2 h, and 100% lethality was observed in 1 h at 100 ng (3 µM). The neurotoxicity observed at Lei-Dab7 concentrations higher than 1500 nM may be due to the blockade of SKCa1 and/or SKCa3 homotetrameric channels (Table II), although we cannot exclude the contribution of heteromultimeric SKCa channels containing SKCa2 subunits.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Functional SKCa channels are tetramers of SKCa1-3 subunits that can assemble as homo- or heterooligomers (39). Heterooligomers are likely to exist natively given the overlapping patterns of distribution of SKCa1-3 in the central nervous system. SKCa1 and SKCa2 are abundant in the hippocampus, whereas the medial habenula has both SKCa2 and SKCa3 (10, 16). The available SKCa channel inhibitors, including apamin (3, 22, 25, 26) and the UCL compounds (7, 25), do not have the requisite selectivity to define the specific functional roles of the homo- and heterooligomeric SKCa channels present in mammalian tissues. In this study, we used a structure-guided approach to develop Lei-Dab7, a novel peptide that blocks SKCa2 homotetramers with nanomolar potency and exhibits 650-fold or greater selectivity over related homooligomeric channels. Heterooligomeric SKCa channels may exhibit intermediate sensitivity for Lei-Dab7 compared with their homotetrameric counterparts as has been shown with apamin on recombinant heterotetramers of SKCa1 and SKCa2 (39).

Lei-Dab7 might help elucidate the contributions of SKCa2 channels in mediating neuronal afterhyperpolarization (3-5) and in the apamin-induced destruction of cerebellar Purkinje neurons (17) and altered seizure threshold (18, 19). Lei-Dab7 may also help define the role of SKCa2 in the retina, liver, melanocytes, immune system, and fetal heart. The subunit composition of SKCa heterooligomers in diverse mammalian tissues may also be determined by using Lei-Dab7 in much the same way as radiolabeled peptide toxins selective for a particular KV subunit have proven useful in assessing the subunit composition of brain heteromeric KV channels (40-42).

Peptide inhibitors of SKCa channels form a structurally distinct group and lack the conserved dyad present in peptide blockers of KV, IKCa1, and BKCa channels that consists of an aromatic residue with a neighboring invariant lysine (43). Therefore, the architecture of the toxin-binding surface in the external vestibule of SKCa channels may differ from that of KV (44-47) and IKCa1 (28, 48) channels, which are similar to that of the crystallographically defined structure of the bacterial K+ channel, KcsA (49, 50). The topologies of KV and IKCa1 channels were deduced from toxin mapping studies by identifying multiple contact points between toxins of known structure and these channels. Lei-Dab7 may similarly be used as a molecular caliper to delineate the architecture of the external vestibule of SKCa2 . Molecular models of SKCa channels based on complementary mutagenesis studies would facilitate the development of selective and potent inhibitors of SKCa1 and SKCa3.

    ACKNOWLEDGEMENTS

We thank Chialing Wu and Dr. Luette Forrest for technical assistance, Dr. Pascal Mansuelle for amino acid analyses and Edman sequencing, and Prof. Herve Rochat for constant support.

    FOOTNOTES

* This study was supported by Grant MH59222 from the National Institutes of Health (to K. G. C.), by an American Heart Association Fellowship (to H. W.), and by CNRS and Cellpep S.A. (Paris, France) funds.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These two authors contributed equally to this work and should be considered co-first authors.

To whom correspondence should be addressed: Rm. 291, Joan Irvine Smith Hall, Medical School, University of California, Irvine, CA 92697. Tel.: 949-824-2133; Fax: 949-824-3143; E-mail: vshakkot@uci.edu.

Published, JBC Papers in Press, August 29, 2001, DOI 10.1074/jbc.M106981200

    ABBREVIATIONS

The abbreviations used are: KCa, calcium-activated K+ channel; SKCa, small conductance KCa; BKCa, large conductance KCa; IKCa, intermediate conductance KCa; Lei, leiurotoxin I; Dab, diaminobutanoic acid; Dapa, diaminopropionic acid; GFP, green fluorescent protein; Fmoc, N-(9-fluorenyl)methoxycarbonyl; HPLC, high-pressure liquid chromatography.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Latorre, R., Oberhauser, A., Labarca, P., and Alvarez, O. (1989) Annu. Rev. Physiol. 51, 385-399[CrossRef][Medline] [Order article via Infotrieve]
2. Hirschberg, B., Maylie, J., Adelman, J. P., and Marrion, N. V. (1998) J. Gen. Physiol. 111, 565-581[Abstract/Free Full Text]
3. Kohler, M., Hirschberg, B., Bond, C. T., Kinzie, J. M., Marrion, N. V., Maylie, J., and Adelman, J. P. (1996) Science 273, 1709-1714[Abstract/Free Full Text]
4. Sah, P. (1996) Trends Neurosci. 19, 150-154[CrossRef][Medline] [Order article via Infotrieve]
5. Xia, X. M., Fakler, B., Rivard, A., Wayman, G., Johnson-Pais, T., Keen, J. E., Ishii, T., Hirschberg, B., Bond, C. T., Lutsenko, S., Maylie, J., and Adelman, J. P. (1998) Nature 395, 503-507[CrossRef][Medline] [Order article via Infotrieve]
6. Barfod, E. T., Moore, A. L., and Lidofsky, S. D. (2001) Am. J. Physiol. 280, C836-C842[Abstract/Free Full Text]
7. Fanger, C. M., Rauer, H., Neben, A. L., Miller, M. J., Rauer, H., Wulff, H., Rosa, J. C., Ganellin, C. R., Chandy, K. G., and Cahalan, M. D. (2001) J. Biol. Chem. 276, 12249-12256[Abstract/Free Full Text]
8. Pribnow, D., Johnson-Pais, T., Bond, C. T., Keen, J., Johnson, R. A., Janowsky, A., Silvia, C., Thayer, M., Maylie, J., and Adelman, J. P. (1999) Muscle Nerve 22, 742-750[CrossRef][Medline] [Order article via Infotrieve]
9. Kimura, T., Takahashi, M. P., Okuda, Y., Kaido, M., Fujimura, H., Yanagihara, T., and Sakoda, S. (2000) Neurosci. Lett. 295, 93-96[CrossRef][Medline] [Order article via Infotrieve]
10. Rimini, R., Rimland, J. M., and Terstappen, G. C. (2000) Brain Res. 85, 218-220[CrossRef]
11. Jenkinson, D. H., Haylett, D. G., and Cook, N. S. (1983) Cell Calcium 4, 429-437[CrossRef][Medline] [Order article via Infotrieve]
12. Paolocci, N., Pagliaro, P., Isoda, T., Saavedra, F. W., and Kass, D. A. (2001) Circulation 103, 119-124[Abstract/Free Full Text]
13. Nagayama, T., Fukushima, Y., Hikichi, H., Yoshida, M., Suzuki-Kusaba, M., Hisa, H., Kimura, T., and Satoh, S. (2000) Am. J. Physiol. 279, R1731-R1736[Abstract/Free Full Text]
14. Grissmer, S., Lewis, R. S., and Cahalan, M. D. (1992) J. Gen. Physiol. 99, 63-84[Abstract/Free Full Text]
15. Hanselmann, C., and Grissmer, S. (1996) J. Physiol. (Lond.) 496, 627-637[Abstract/Free Full Text]
16. Stocker, M., and Pedarzani, P. (2000) Mol. Cell. Neurosci. 15, 476-493[CrossRef][Medline] [Order article via Infotrieve]
17. Mourre, C., Fournier, C., and Soumireu-Mourat, B. (1997) Brain Res. 778, 405-408[CrossRef][Medline] [Order article via Infotrieve]
18. McCown, T. J., and Breese, G. R. (1990) Eur. J. Pharmacol. 187, 49-58[CrossRef][Medline] [Order article via Infotrieve]
19. Empson, R., and Jefferys, J. (2001) Neuroscience 102, 297-306[CrossRef][Medline] [Order article via Infotrieve]
20. Sabatier, J. M., Fremont, V., Mabrouk, K., Crest, M., Darbon, H., Rochat, H., Van Rietschoten, J., and Martin-Eauclaire, M. F. (1994) Int. J. Pept. Protein Res. 43, 486-495[Medline] [Order article via Infotrieve]
21. Klocker, N., Oliver, D., Ruppersberg, J., Knaus, H., and Fakler, B. (2001) Mol. Cell. Neurosci. 17, 514-520[CrossRef][Medline] [Order article via Infotrieve]
22. Desai, R., Peretz, A., Idelson, H., Lazarovici, P., and Attali, B. (2000) J. Biol. Chem. 275, 39954-39963[Abstract/Free Full Text]
23. Jaeger, H., Adelman, J. P., and Grissmer, S. (2000) FEBS Lett. 469, 196-202[CrossRef][Medline] [Order article via Infotrieve]
24. Grissmer, S., Nguyen, A. N., and Cahalan, M. D. (1993) J. Gen. Physiol. 102, 601-630[Abstract/Free Full Text]
25. Stroebaek, D., Joergensen, T. D., Christophersen, P., Ahring, P. K., and Olesen, S. P. (2000) Br. J. Pharmacol. 129, 991-999[CrossRef][Medline] [Order article via Infotrieve]
26. Shah, M., and Haylett, D. G. (2000) Br. J. Pharmacol. 129, 627-630[CrossRef][Medline] [Order article via Infotrieve]
27. Kalman, K., Pennington, M. W., Lanigan, M. D., Nguyen, A., Rauer, H., Mahnir, V., Paschetto, K., Kem, W. R., Grissmer, S., Gutman, G. A., Christian, E. P., Cahalan, M. D., Norton, R. S., and Chandy, K. G. (1998) J. Biol. Chem. 273, 32697-32707[Abstract/Free Full Text]
28. Rauer, H., Lanigan, M. D., Pennington, M. W., Aiyar, J., Ghanshani, S., Cahalan, M. D., Norton, R. S., and Chandy, K. G. (2000) J. Biol. Chem. 275, 1201-1208[Abstract/Free Full Text]
29. Merrifield, B. (1986) Science 232, 341-347[Free Full Text]
30. Chandy, K. G., Fantino, E., Wittekindt, O., Kalman, K., Tong, L. L., Ho, T. H., Gutman, G. A., Crocq, M. A., Ganguli, R., Nimgaonkar, V., Morris- Rosendahl, D. J., and Gargus, J. J. (1998) Mol. Psychiatry 3, 32-37[CrossRef][Medline] [Order article via Infotrieve]
31. Logsdon, N. J., Kang, J., Togo, J. A., Christian, E. P., and Aiyar, J. (1997) J. Biol. Chem. 272, 32723-32726[Abstract/Free Full Text]
32. Ghanshani, S., Coleman, M., Gustavsson, P., Wu, A. C., Gargus, J. J., Gutman, G. A., Dahl, N., Mohrenweiser, H., and Chandy, K. G. (1998) Genomics 51, 160-161[CrossRef][Medline] [Order article via Infotrieve]
33. Behrens, B., and Karber, C. (1935) Arch. Exp. Pathol. Pharmakol. 177, 379-388
34. Fajloun, Z., Carlier, E., Lecomte, C., Geib, S., Di Luccio, E., Bichet, D., Mabrouk, K., Rochat, H., De Waard, M., and Sabatier, J. M. (2000) Eur. J. Biochem. 267, 5149-5155[Medline] [Order article via Infotrieve]
35. Tytgat, J., Chandy, K., Garcia, M., Gutman, G., Martin-Eauclaire, M., van der Walt, J., and Possani, L. (2000) Trends Pharmacol. Sci. 20, 444-447
36. Sabatier, J. M., Zerrouk, H., Darbon, H., Mabrouk, K., Benslimane, A., Rochat, H., Martin-Eauclaire, M. F., and Van Rietschoten, J. (1993) Biochemistry 32, 2763-2770[CrossRef][Medline] [Order article via Infotrieve]
37. Rajamohan, F., Alzate, O., Cotrill, J. A., Curtiss, A., and Dean, D. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14338-14343[Abstract/Free Full Text]
38. Smith, L. A., Reid, P. F., Wang, F. C., Parcej, D. N., Schmidt, J. J., Olson, M. A., and Dolly, J. O. (1997) Biochemistry 36, 7690-7696[CrossRef][Medline] [Order article via Infotrieve]
39. Ishii, T. M., Maylie, J., and Adelman, J. P. (1997) J. Biol. Chem. 272, 23195-23200[Abstract/Free Full Text]
40. Scott, V. E., Muniz, Z. M., Sewing, S., Lichtinghagen, R., Parcej, D. N., Pongs, O., and Dolly, J. O. (1994) Biochemistry 33, 1617-1623[CrossRef][Medline] [Order article via Infotrieve]
41. Koschak, A., Bugianesi, R. M., Mitterdorfer, J., Kaczorowski, G. J., Garcia, M. L., and Knaus, H. G. (1998) J. Biol. Chem. 273, 2639-2644[Abstract/Free Full Text]
42. Koch, R. O., Wanner, S. G., Koschak, A., Hanner, M., Schwarzer, C., Kaczorowski, G. J., Slaughter, R. S., Garcia, M. L., and Knaus, H. G. (1997) J. Biol. Chem. 272, 27577-27581[Abstract/Free Full Text]
43. Dauplais, M., Lecoq, A., Song, J., Cotton, J., Jamin, N., Gilquin, B., Roumestand, C., Vita, C., de Medeiros, C. L. C., Rowan, E. G., Harvey, A. L., and Menez, A. (1997) J. Biol. Chem. 272, 4302-4309[Abstract/Free Full Text]
44. Aiyar, J., Withka, J. M., Rizzi, J. P., Singleton, D. H., Andrews, G. C., Lin, W., Boyd, J., Hanson, D. C., Simon, M., Dethlefs, B., Lee, C.-L., Hall, J. E., Gutman, G. A., and Chandy, K. G. (1995) Neuron 15, 1169-1181[CrossRef][Medline] [Order article via Infotrieve]
45. Aiyar, J., Rizzi, J. P., Gutman, G. A., and Chandy, K. G. (1996) J. Biol. Chem. 271, 31013-31016[Abstract/Free Full Text]
46. Hidalgo, P., and MacKinnon, R. (1995) Science 268, 307-310[Abstract/Free Full Text]
47. Ranganathan, R., Lewis, J. H., and MacKinnon, R. (1996) Neuron 16, 131-139[CrossRef][Medline] [Order article via Infotrieve]
48. Rauer, H., Pennington, M., Cahalan, M., and Chandy, K. G. (1999) J. Biol. Chem. 274, 21885-21892[Abstract/Free Full Text]
49. Doyle, D. A., Morais Cabral, J., Pfuetzner, R. A., Kuo, A., Gulbis, J. M., Cohen, S. L., Chait, B. T., and MacKinnon, R. (1998) Science 280, 69-77[Abstract/Free Full Text]
50. MacKinnon, R., Cohen, S. L., Kuo, A., Lee, A., and Chait, B. T. (1998) Science 280, 106-109[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
A. Nolting, T. Ferraro, D. D'hoedt, and M. Stocker
An Amino Acid Outside the Pore Region Influences Apamin Sensitivity in Small Conductance Ca2+-activated K+ Channels
J. Biol. Chem., February 9, 2007; 282(6): 3478 - 3486.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Potier, V. Joulin, S. Roger, P. Besson, M.-L. Jourdan, J.-Y. LeGuennec, P. Bougnoux, and C. Vandier
Identification of SK3 channel as a new mediator of breast cancer cell migration.
Mol. Cancer Ther., November 1, 2006; 5(11): 2946 - 2953.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. Strobaek, C. Hougaard, T. H. Johansen, U. S. Sorensen, E. O. Nielsen, K. S. Nielsen, R. D. T. Taylor, P. Pedarzani, and P. Christophersen
Inhibitory Gating Modulation of Small Conductance Ca2+-Activated K+ Channels by the Synthetic Compound (R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) Reduces Afterhyperpolarizing Current in Hippocampal CA1 Neurons
Mol. Pharmacol., November 1, 2006; 70(5): 1771 - 1782.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-Q. Xu, B. Brone, D. Wicher, O. Bozkurt, W.-Y. Lu, I. Huys, Y.-H. Han, J. Tytgat, E. Van Kerkhove, and C.-W. Chi
BmBKTx1, a Novel Ca2+-activated K+ Channel Blocker Purified from the Asian Scorpion Buthus martensi Karsch
J. Biol. Chem., August 13, 2004; 279(33): 34562 - 34569.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Sultan, M. Gosling, S. Abu-Hayyeh, N. Carey, and J. T. Powell
Flow-dependent increase of ICAM-1 on saphenous vein endothelium is sensitive to apamin
Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H22 - H28.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
E. A. Kramar, B. Lin, C.-Y. Lin, A. C. Arai, C. M. Gall, and G. Lynch
A Novel Mechanism for the Facilitation of Theta-Induced Long-Term Potentiation by Brain-Derived Neurotrophic Factor
J. Neurosci., June 2, 2004; 24(22): 5151 - 5161.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. D'hoedt, K. Hirzel, P. Pedarzani, and M. Stocker
Domain Analysis of the Calcium-activated Potassium Channel SK1 from Rat Brain: FUNCTIONAL EXPRESSION AND TOXIN SENSITIVITY
J. Biol. Chem., March 26, 2004; 279(13): 12088 - 12092.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
O. H. Wittekindt, V. Visan, H. Tomita, F. Imtiaz, J. J. Gargus, F. Lehmann-Horn, S. Grissmer, and D. J. Morris-Rosendahl
An Apamin- and Scyllatoxin-Insensitive Isoform of the Human SK3 Channel
Mol. Pharmacol., March 1, 2004; 65(3): 788 - 801.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. A. Castle, D. O. London, C. Creech, Z. Fajloun, J. W. Stocker, and J.-M. Sabatier
Maurotoxin: A Potent Inhibitor of Intermediate Conductance Ca2+-Activated Potassium Channels
Mol. Pharmacol., February 1, 2003; 63(2): 409 - 418.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Pedarzani, D. D'hoedt, K. B. Doorty, J. D. F. Wadsworth, J. S. Joseph, K. Jeyaseelan, R. M. Kini, S. V. Gadre, S. M. Sapatnekar, M. Stocker, et al.
Tamapin, a Venom Peptide from the Indian Red Scorpion (Mesobuthus tamulus) That Targets Small Conductance Ca2+-activated K+ Channels and Afterhyperpolarization Currents in Central Neurons
J. Biol. Chem., November 22, 2002; 277(48): 46101 - 46109.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/46/43145    most recent
M106981200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shakkottai, V. G.
Right arrow Articles by Chandy, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shakkottai, V. G.
Right arrow Articles by Chandy, K. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement